ECOR vs. ZIMV, CVRX, NPCE, SMTI, LUNG, ELMD, DRTS, ZYXI, INGN, and NYXH
Should you be buying electroCore stock or one of its competitors? The main competitors of electroCore include ZimVie (ZIMV), CVRx (CVRX), NeuroPace (NPCE), Sanara MedTech (SMTI), Pulmonx (LUNG), Electromed (ELMD), Alpha Tau Medical (DRTS), Zynex (ZYXI), Inogen (INGN), and Nyxoah (NYXH). These companies are all part of the "medical equipment" industry.
electroCore vs.
ZimVie (NASDAQ:ZIMV) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk.
electroCore received 162 more outperform votes than ZimVie when rated by MarketBeat users. Likewise, 62.26% of users gave electroCore an outperform vote while only 18.75% of users gave ZimVie an outperform vote.
In the previous week, electroCore had 1 more articles in the media than ZimVie. MarketBeat recorded 3 mentions for electroCore and 2 mentions for ZimVie. ZimVie's average media sentiment score of 1.78 beat electroCore's score of 0.86 indicating that ZimVie is being referred to more favorably in the media.
ZimVie has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, electroCore has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.
95.6% of ZimVie shares are owned by institutional investors. Comparatively, 26.7% of electroCore shares are owned by institutional investors. 5.0% of ZimVie shares are owned by insiders. Comparatively, 19.7% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ZimVie currently has a consensus price target of $19.50, indicating a potential upside of 36.46%. electroCore has a consensus price target of $25.00, indicating a potential upside of 57.23%. Given electroCore's stronger consensus rating and higher probable upside, analysts clearly believe electroCore is more favorable than ZimVie.
electroCore has a net margin of -54.40% compared to ZimVie's net margin of -77.31%. ZimVie's return on equity of 2.90% beat electroCore's return on equity.
electroCore has lower revenue, but higher earnings than ZimVie. electroCore is trading at a lower price-to-earnings ratio than ZimVie, indicating that it is currently the more affordable of the two stocks.
Summary
electroCore beats ZimVie on 10 of the 17 factors compared between the two stocks.
Get electroCore News Delivered to You Automatically
Sign up to receive the latest news and ratings for ECOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
electroCore Competitors List
Related Companies and Tools
This page (NASDAQ:ECOR) was last updated on 1/20/2025 by MarketBeat.com Staff
Free ECOR Stock Alerts